'Cutting Edge’ T-knife Gets €66m Series A Financing
To Fund Biotech’s Next-Generation Mouse-Based T-Cell Therapies
Executive Summary
T-knife, a developer of T-cell receptors intended for T-cell therapy in solid tumor cancers, says the series A gives its development program three years of financial runway.